Although proinflammatory and chemotactic cytokines can profoundly affect the tumor
microenvironment, and many of them have been shown to have therapeutic efficacy in …

Background Waldenström macroglobulinemia (WM) is a rare and incurable indolent B-cell
malignancy. The molecular pathogenesis and the role of immunosuppressive …

Waldenström's macroglobulinemia (WM) is a lymphoplasmacytic lymphoma characterized
by the overproduction of a monoclonal IgM protein that accumulates in the serum. Although …

Waldenström macroglobulinemia (WM) is a B-cell malignancy characterized by the ability
of the B-cell clone to differentiate into plasma cells. Although the clinical syndrome and the …

Recent investigations have improved our understanding of the molecular aberrations
supporting Waldenström macroglobulinemia (WM) biology; however, whether the immune …

To better understand the molecular changes that occur in Waldenstrom macroglobulinemia
(WM), we employed antibody-based protein microarrays to compare patterns of protein …

Next-generation sequencing has revealed recurring somatic mutations in Waldenström
macroglobulinemia (WM). Commonly recurring mutations include MYD88 (95% to 97%) …

Waldenström macroglobulinemia (WM) is characterized by bone marrow (BM) infiltration of
monoclonal Immunoglobulin M (IgM) secreting lymphoplasmacytic lymphoma (LPL), and …

It is one of the major aims in cancer research to improve our understanding of the underlying
mechanisms which initiate and maintain tumor growth and to translate these findings into …

Waldenström's macroglobulinemia (WM) is a distinct clinicobiological entity defined as a B-
cell neoplasm characterized by a lymphoplasmacytic infiltrate in bone marrow (BM) and IgM …